Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR - Health Canada Drug Approval Details

Approvals/Health Canada/RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR

Authorized

STANDARD

RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR

laboratoire riva inc.🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 8db21c7d2300a02b
Company: laboratoire riva inc.
Type: Standard

Approval Details

Approval Id: 8db21c7d2300a02b
Drug Approval Canada Name: RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
Product Name: RIVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
Status: Marketed
Status Date: 2021-08-25
Original Market Date: 2021-08-25
Din: 02518716
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 08:18.08.16
Atc Original: J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ
Atc Name: j 05 ar 06
Aig Number: 0352327001
Company Name: laboratoire riva inc.
Company Address: 660 Boul. Industriel, Blainville, Quebec, Canada, J7C 3V4

Active Ingredients

EMTRICITABINE

200 MG

EFAVIRENZ

600 MG

TENOFOVIR DISOPROXIL FUMARATE

300 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

8db21c7d2300a02b

Type

Standard

Back to Health Canada Approvals